Source comparison
TB-500 for Climbers: Comparison with BPC-157 and Growth Factors
TB-500 Actin binding, cellular migration, VEGF upregulation Tendons, ligaments, muscle 2–2.5mg twice weekly Subacute to chronic (week 2 onward) Equine RCTs, rodent models, no human trials BPC-157 Gastric signaling, angiogenesis, nitric oxide modulation Gastric
This comparison does not assign a generated winner or score.
- TB-500
- Actin binding, cellular migration, VEGF upregulation
- Tendons, ligaments, muscle
- 2–2.5mg twice weekly
- Subacute to chronic (week 2 onward)
- Equine RCTs, rodent models, no human trials
- BPC-157
- Gastric signaling, angiogenesis, nitric oxide modulation
- Gastric mucosa, tendons, ligaments
- 250–500mcg daily
- Acute to subacute (day 1 onward)
- Rodent models only, no human or veterinary trials
- IGF-1 LR3
- Insulin-like growth factor receptor activation, satellite cell proliferation
- Muscle hypertrophy, cartilage
- 40–80mcg daily
- Chronic overuse, not acute injury
- Bovine trials, limited human data
- PRP Injections
- Autologous platelet-derived growth factors, localized inflammation modulation
- Site-specific: injected tissue only
- Single injection or 3-injection series
- Acute to chronic
- Multiple human RCTs in tendinopathy
- Climbers researching TB-500 often compare it to BPC-157 because both are investigated for tendon recovery, but the mechanisms diverge significantly. BPC-157 promotes angiogenesis through nitric oxide and VEGF pathways similar to TB-500, but it also interacts with the gastric mucosal cytoprotective system. Its effects on tendon healing may be secondary rather than primary. BPC-157 has zero veterinary trial data and no published human studies, while TB-500 has been used in racehorses for decades with documented tendon outcomes.
- PRP (platelet-rich plasma) injections remain the only evidence-based intervention with Level 1 human trial data for lateral epicondylitis and patellar tendinopathy. A 2021 meta-analysis in British Journal of Sports Medicine found PRP reduced pain scores by 2.1 points on the VAS scale compared to 0.8 for saline in chronic tendon injuries. The primary limitation: PRP requires clinical administration and costs $500–$1,500 per session, while research peptides are self-administered and substantially less expensive per protocol cycle.